MRI contrast developer Epix Pharmaceuticals has begun a phase II proof-of-concept trial for its EP-2104R injectable MRI agent, designed to detect blood clots throughout the body.
The phase II program is being conducted at multiple clinical sites worldwide to further test safety and preliminary efficacy of the agent for evaluating blood clots in patients presenting with strong suspicion of clots from thromboembolic disease, according to the Cambridge, MA-based firm. About 40 patients are expected to be enrolled in the trial.
By AuntMinnie.com staff writers
April 7, 2005
Related Reading
Epix signs DeWitt, April 5, 2005
Bracco dispute trims Epix revenues, February 18, 2005
Epix hit with class-action lawsuit, January 28, 2005
Epix gets approvable letter, January 14, 2005
Epix shows Q3 downturn, October 27, 2004
Copyright © 2005 AuntMinnie.com
